January 11, 2017
Janssen Pharmaceutical announced on January 6 that it will initiate joint research with Fukushima Medical University to develop diagnostic biomarkers for adult attention deficit hyperactivity disorder (ADHD). The three year research period will extend through December 2019. ADHD is currently...read more